摘要
目的:探讨阿扎胞苷联合CAG方案治疗老年急性髓系白血病(acute myeloid leukemia,AML)的临床治疗效果及治疗后对血液学指标的影响和安全性。方法:101例研究对象选自我院2019年01月至2022年01月接诊的老年AML患者,随机分为联合组(n=55)和对照组(n=46),联合组老年AML患者予以阿扎胞苷联合CAG方案治疗,对照组老年AML患者予以单一CAG方案治疗。对比两组老年AML患者临床治疗效果、血液学指标白细胞计数(WBC)、血红蛋白(Hb)、血小板计数(PC)、中性粒细胞恢复时间、血小板输注量、血小板恢复时间、安全性、生存质量评分。结果:经28 d治疗后,联合组老年AML患者总缓解率高于对照组老年AML患者(90.91%vs 63.04%)(P<0.05);联合组WBC和PC高于对照组,而联合组Hb低于对照组(P<0.05);联合组老年AML患者血小板输注量、血小板恢复时间及中性粒细胞恢复时间均低于对照组老年AML患者(P<0.05);联合组和对照组老年AML患者总不良反应率对比无显著差异(14.55%vs 15.22%)(P>0.05);联合组老年AML患者生存质量评分高于对照组老年AML患者(P<0.05);联合组术后1年生存率72.73%(40/55)明显高于对照组52.17%(24/46)(P<0.05)。结论:CAG方案联合阿扎胞苷治疗对老年AML患者具有较高的安全性,且能够改善患者血液学指标,减少血小板输注量,缩短血小板恢复时间及中性粒细胞恢复时间。同时联合治疗还可能增加患者生存时间。
Objective:To investigate the clinical therapeutic effect of azacytoside combined with CAG regimen in the treatment of elderly acute myeloid leukemia(AML),and the influence and safety of hematologic indexes after treatment.Methods:A total of 101 elderly AML patients admitted to our hospital from January 2019 to January 2022 were randomly divided into a combined group(n=55)and a control group(n=46).Elderly AML patients in the combination group were treated with azacytoside combined with CAG regimen,while elderly AML patients in the control group were treated with single CAG regimen.The clinical therapeutic effect,blood indexes,neutrophil recovery time,platelet infusion volume,platelet recovery time,safety and quality of life scores of the two groups of elderly AML patients were compared.Results:After 28 days of treatment,the total remission rate of elderly AML patients in the combined group was higher than that in the control group(90.91%vs 63.04%)(P<0.05).The white blood cell count and platelet count of the combined group were higher than those of the control group,while the hemoglobin of the combined group was lower than that of the control group(P<0.05).The platelet transfusion volume,platelet recovery time and neutrophil recovery time of the combined group were significantly lower than those of the control group(P<0.05).There was no significant difference in the total adverse reactions between combined group and control group(14.55%vs 15.22%)(P>0.05).The quality of life score of elderly AML patients in combined group was higher than that in control group(P<0.05).The 1-year survival rate of the combined group was 72.73%(40/55),which was significantly higher than that of the control group 52.17%(24/46)(P<0.05).Conclusion:CAG regimen combined with azacitidine therapy has high safety in elderly AML patients,and can improve patients'hematological indexes,reduce platelet transfusion volume,and shorten platelet recovery time and neutrophil recovery time.Combination therapy may also increase survival time.
作者
梁波
LIANG Bo(Hematology Department,Xinxiang Central Hospital,Henan Xinxiang 453000,China)
出处
《现代肿瘤医学》
CAS
北大核心
2023年第15期2879-2883,共5页
Journal of Modern Oncology
